DUBLIN–(BUSINESS WIRE)–The “Chronic Hepatitis B Virus Infection – Pipeline Insight, 2021” clinical trials has been added to ResearchAndMarkets.com’s offering.
This report provides comprehensive insights about 45+ companies and 45+ pipeline drugs in Chronic Hepatitis B Virus Infection pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Chronic hepatitis B virus infection is a global public health threat that causes considerable liver-related morbidity and mortality. It is acquired at birth or later via person-to-person transmission. Vaccination effectively prevents infection and chronic hepatitis B virus carriage. In chronically infected patients, an elevated serum hepatitis B virus DNA concentration is the main risk factor for disease progression, although there are other clinical and viral parameters that influence disease outcomes. In addition to liver biochemistry, virological markers, and abdominal ultrasonography, non-invasive assessment of liver fibrosis is emerging as an important assessment modality. Long-term nucleos(t)ide-analogue therapy is safe and well tolerated, achieves potent viral suppression, and reduces the incidence of liver-related complications. However, a need to optimise management remains. Promising novel therapies are at the developmental stage.
Chronic Hepatitis B Virus Infection – Pipeline Insight, 2021 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chronic Hepatitis B Virus Infection pipeline landscape is provided which includes the disease overview and Chronic Hepatitis B Virus Infection treatment guidelines. The assessment part of the report embraces, in depth Chronic Hepatitis B Virus Infection commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chronic Hepatitis B Virus Infection collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Chronic Hepatitis B Virus Infection R&D. The therapies under development are focused on novel approaches to treat/improve Chronic Hepatitis B Virus Infection.
Chronic Hepatitis B Virus Infection Emerging Drugs Chapters
This segment of the Chronic Hepatitis B Virus Infection report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chronic Hepatitis B Virus Infection Emerging Drugs
AB-729 (GalNAc-RNAi): Arbutus Biopharma
AB-729 is a subcutaneously-delivered RNAi therapeutic targeted to hepatocytes that inhibits viral replication and reduces all HBV antigens using our novel covalently conjugated GalNAc delivery technology. Currently, it is in Phase II stage of development to treat Chronic Hepatitis B virus infection.
VIR-2218: Vir Biotechnology
VIR-2218, an HBV-targeting siRNA, is designed to inhibit the production of all HBV proteins, including hepatitis B virus surface antigen (HBsAg), which in turn is hypothesized to remove the inhibition of T cell activity directed against HBV. We believe that achieving a functional cure for many HBV patients may be enabled by using VIR-2218 in combination with other agents. Currently, it is in Phase II stage of development to treat Chronic Hepatitis B virus infection.
Key Questions Answered
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chronic Hepatitis B Virus Infection drugs?
- How many Chronic Hepatitis B Virus Infection drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chronic Hepatitis B Virus Infection?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chronic Hepatitis B Virus Infection therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chronic Hepatitis B Virus Infection and their status?
- What are the key designations that have been granted to the emerging drugs?
Key Players
- Arbutus Biopharma
- Vir Biotechnology
- Ascentage Pharma Group Inc.
- Assembly Biosciences
- Nucorion Pharmaceuticals, Inc.
- Hoffmann-La Roche
- Enyo Pharma
- Qilu Pharmaceutical Co., Ltd.
- Ascletis Pharmaceuticals Co., Ltd.
- Xiamen Amoytop Biotech
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Romark Laboratories L.C.
- Alios Biopharma Inc.
- Antios Therapeutics, Inc
- Jiangsu HengRui Medicine Co., Ltd.
- Enanta Pharmaceuticals
- Janssen Pharmaceuticals
- Gilead Sciences
- Replicor Inc.
- Golden Biotechnology Corporation
- Hepatera Ltd.
- PharmaEssentia
- Chong Kun Dang Pharmaceutical
- Green Cross Corporation
- Aligos Therapeutics
- Sunshine Lake Pharma Co., Ltd.
- Transgene
- Tasly Tianjin Biopharmaceutical Co., Ltd.
- GlaxoSmithKline
- Henlix, Inc
- Ionis Pharmaceuticals, Inc.
- Altimmune, Inc.
- Shanghai HEP Pharmaceutical
- Dong-A ST Co., Ltd.
- Enyo Pharma
- CHA Vaccine Institute Co., Ltd.
- Dicerna Pharmaceuticals, Inc.
- Vaccitech (UK) Limited
- Fujian Cosunter Pharmaceutical Co. Ltd
- Regeneron Pharmaceuticals
- VenatoRx Pharmaceuticals
- ISA Pharmaceuticals
- Finch Therapeutics Group, Inc
- Zhimeng Biopharma
- VBI Vaccines Inc
- GlobeImmune
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/rk0z4i
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900